

Company Overview

DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase 2 clinical trial for the treatment of Unmethylated MGMT refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and other solid tumors, including ovarian cancer and pediatric CNS tumors.

DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM

Feb 20 2019, 5:30 AM EST

DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results

Feb 12 2019, 5:30 AM EST

DelMar Pharmaceuticals Receives Nasdaq Listing Extension

Feb 7 2019, 5:30 AM EST

Stock Overview

Symbol	DMPI
Exchange	Nasdaq
Market Cap	8.49m
Last Price	\$0.332
52-Week	\$0.31 - \$1.38

02/21/2019 04:00 PM EST

Investor Relations

T: (604) 629-5989
ir@delmarpharma.com

Management Team

Saïd Zarrabian

President and Chief Executive Officer, Director

Dennis M. Brown, Ph.D.

Chief Scientific Officer

Scott Prail, C.P.A.

Chief Financial Officer

DelMar Pharmaceuticals, Inc.

Suite 720 - 999 West Broadway
Vancouver, B.C., Canada, V5Z 1K5

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.